JAP Spijkers-Hagelstein, S Mimoso Pinhanc¸os, P Schneider, R Pieters and RW Stam MLL-rearranged infant acute lymphoblastic leukemia (ALL) (o1 year of age) are frequently resistant to glucocorticoids, like prednisone and dexamethasone. As poor glucocorticoid responses are strongly associated with therapy failure, overcoming glucocorticoid resistance may be a crucial step towards improving prognosis. Unfortunately, the mechanisms underlying glucocorticoid resistance in MLL-rearranged ALL largely remain obscure. We here defined a gene signature that accurately discriminates between prednisolone-resistant and prednisolone-sensitive MLL-rearranged infant ALL patient samples, demonstrating that, among other genes, high-level ANXA2 is associated with prednisolone resistance in this type of leukemia. Further investigation demonstrated that the underlying factor of this association was the presence of Src kinase-induced phosphorylation (activation) of annexin A2, a process requiring the adapter protein p11 (encoded by human S100A10). shRNAmediated knockdown of either ANXA2, FYN, LCK or S100A10, all led to inhibition of annexin A2 phosphorylation and resulted in marked sensitization to prednisolone. Likewise, exposure of prednisolone-resistant MLL-rearranged ALL cells to different Src kinase inhibitors exerting high specificity towards FYN and/or LCK had similar effects. In conclusion, we here present a novel mechanism of prednisolone resistance in MLL-rearranged leukemias, and propose that inhibition of annexin A2 phosphorylation embodies a therapeutic strategy for overcoming resistance to glucocorticoids in this highly aggressive type of leukemia.
INTRODUCTION
Glucocorticoids (for example, prednisolone and dexamethasone) are successfully used in the treatment of childhood acute lymphoblastic leukemia (ALL), and represent extremely important agents in current combination chemotherapy regimes. Although most pediatric ALL patients respond well to glucocorticoid-based therapies, some subsets of patients appeared highly resistant to these drugs. A characteristic group of ALL patients highly resistant to glucocorticoids, and as such notoriously difficult to treat, involve infants (o1 year of age) carrying leukemia-specific chromosomal translocations of the Mixed Lineage Leukemia (MLL) gene. MLL-rearranged infant ALL cells are often characterized by cellular resistance to glucocorticoids, 1, 2 and approximately one-third of all infant ALL cases show a poor in vivo response to a 7-day window of prednisone monotherapy. 3 In contrast, among wild-type MLL childhood ALL patients, a poor in vivo prednisone response is only observed in B10% of the cases. Currently facing survival chances of at best B50%, 4 this particular group of patients would surely benefit from glucocorticoid-sensitizing treatment strategies. As both the in vitro and in vivo glucocorticoid responses have been identified as strong prognostic factors, 3, 5, 6 glucocorticoid resistance remains a major obstacle in reaching optimal treatment results. Unfortunately, the mechanisms underlying glucocorticoid resistance remain largely obscure, which significantly hampers the development of such sensitizing therapies.
In search of insights into glucocorticoid resistance mechanism, we recently compared gene expression profiles from MLL-rearranged infant ALL patients either in vitro resistant or sensitive to prednisolone (the biologically active metabolite of prednisone). This study demonstrated that the gene expression signatures associated with glucocorticoid resistance in MLL-rearranged infant ALL significantly deviate from glucocorticoid-resistance signatures defined in noninfant pediatric precursor B-ALL patients. 7 Moreover, our recently published glucocorticoidresistance signature in MLL-rearranged infant ALL was compromised to some extent by a relatively low accuracy, presumably due to the limited number of patient samples. 7 Therefore, we here set out to produce a stronger glucocorticoidresistance profile for MLL-rearranged infant ALL samples, which more accurately discriminates between patients either resistant or sensitive to prednisolone in vitro. To validate our improved glucocorticoid-resistance profile, we validated one of the genes (that is, ANXA2) prominently overexpressed in prednisoloneresistant MLL-rearranged infant ALL patients. ANXA2, encoding annexin A2, appeared to be represented in our glucocorticoidresistance signature by three different probe sets. Annexin A2, a member of the annexin family of calcium-dependent phospholipid-binding proteins, has important roles in various types of human cancer, including hematopoietic malignancies. For instance, high-level annexin A2 expression has been observed in multiple myeloma cells, in which siRNA-mediated downregulation leads to impaired proliferation and invasion potential, as well as to increased induction of apoptosis. 8 In human breast cancer cells, annexin A2 was markedly upregulated when cells acquired multidrug resistance. 9 In human prostate cancer, annexin A2 expression is usually absent, but upon loss of androgen dependence, annexin A2 is rapidly overexpressed. Inhibiting annexin A2 expression resulted in significant decreases in human prostate tumor growth in mouse models. 10 Finally, annexin A2 phosphorylation (activation) at tyrosine 23 is associated with tumor development and disease progression in pancreatic ductal adenocarcinoma. Interestingly, knockdown of annexin A2, mutations in tyrosine 23 or treatment with anti-ANXA2 antibodies inhibited metastasis and prolonged survival in mouse pancreatic ductal adenocarcinoma models.
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Based on the above, we studied the role of high-level ANXA2 expression in MLL-rearranged ALL. Our results show that elevated expression of ANXA2 is associated with increased levels of phosphorylated (activated) annexin A2 protein expression. Annexin A2 phosphorylation is mediated by Src kinases, a process that requires the presence of the adapter protein p11 (encoded by the S100A10 gene). [12] [13] [14] We demonstrate here that exposing glucocorticoid-resistant MLL-rearranged ALL cells to a variety of known Src kinase inhibitors results in glucocorticoid sensitization. Likewise, shRNA-mediated knockdown of annexin A2, the Src kinases FYN and LCK, or the annexin A2-adapter protein p11, all induce prednisolone sensitivity in otherwise prednisoloneresistant MLL-rearranged cells.
MATERIALS AND METHODS

Patient samples and cell line cultures
Bone marrow and/or peripheral blood samples from untreated infants (that is, children o1 year of age) diagnosed with MLL-rearranged ALL, were collected at Sophia Children's Hospital (Rotterdam, the Netherlands) as part of the international collaborative INTERFANT treatment protocol. 4 Approval for these studies was obtained from the Erasmus MC Institutional Review Board. Informed consent was obtained according to the Declaration of Helsinki. Within 24 h after sampling, mononuclear cells were isolated by density gradient centrifugation, and contaminating nonleukemic cells removed using immunomagnetic beads as described before. 15 All samples used in this study contained more than 90% of leukemic blasts.
The MLL-rearranged ALL cell lines SEM, KOPN8, RS4;11 and BEL-1 were maintained as suspension cultures in RPMI 1640 supplemented with glutamax (Invitrogen, Life Technologies, Breda, the Netherlands), 10% (v/v) fetal calf serum (FCS) and 1% penicillin/streptomycin/fungizone (PSF; Invitrogen, Life Technologies) at 37 1C in humidified air containing 5% CO 2 . SEM, BEL-1, and RS4;11 all carry translocation t(4;11) generating MLL-AF4 fusion proteins. KOPN8 is a t(11;19)-positive ALL line expressing the MLL-ENL fusion. Both SEM and KOPN8 are resistant to prednisolone in vitro, whereas RS4;11 and BEL-1 are highly sensitive.
In vitro prednisolone and in vivo prednisone response
The in vitro prednisolone response was assessed by 4-day MTT assays as described elsewhere. 16 Patient samples were characterized as prednisolone sensitive or resistant based on the LC 50 value (that is, the concentration of prednisolone lethal to 50% of the leukemic cells). Samples were typified as prednisolone-sensitive at LC 50 values o0.1 mg/ml and prednisolone-resistant at LC 50 values 4150 mg/ml.
The in vivo response to prednisolone was determined after a 7-day window of prednisone monotherapy (before the initiation of combination chemotherapy). Patients were defined as prednisone poor responder when 41000 leukemic blasts/l remained present in the peripheral blood at day 7. When the amount of leukemic blasts dropped below 1000/l, patients were defined as prednisone good responder.
Microarray data analysis
A gene expression signature associated with prednisolone resistance in MLL-rearranged infant ALL was produced using a selection of recently generated expression profiles (Affymetrix HU133plus2.0 GeneChips, Santa Clara, CA, USA), deposited in the NCBI Gene Expression Omnibus under the GEO Series accession number GSE32962. 17 Differential gene expression between prednisolone-resistant and prednisolone-sensitive patient samples were statistically evaluated using linear models for microarray analyses. Differences in gene expression were considered significant at P-values o0.05 (adjusted for multiple testing by the false-discovery rate according to the step-up procedure of Benjamini and Hochberg 18 ). Heatmaps were generated in GenePattern 19 and graphical representations of principal component analysis were produced using the GeneMath XT 1.6.1 software (Applied Maths, Sint-Martens-Latem, Belgium).
In vitro assessment of the prednisolone response and sensitization
In vitro prednisolone cytotoxicity was determined by 4-day MTT assays as described before. 16 Briefly, leukemic cells were cultured in 96-well plates in the presence of increasing concentrations of prednisolone (Bufa, Uitgeest, the Netherlands) in duplicate. Controls were cultured in the absence of prednisolone, and wells containing culture medium only were used as blanks. After 4-day incubation periods at 37 1C in humidified air containing 5% CO 2 , 10 ml MTT (5 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) was added and plates were incubated for an additional 6 h during which the yellow MTT tetrazolium salt is reduced to purple-blue formazan crystals by viable cells only. Next, formazan crystals were dissolved and the optical density, which is linearly related to the number of viable cells, was measured on a spectrophotometer. Assay results were deemed successful when a minimum of 70% leukemic cells remained present in the control wells after 4 days of culturing.
Prednisolone-sensitizing effects were determined by performing conventional MTT assays, either in the absence or presence of indicated Src kinase inhibitors. In all instances, observed prednisolone-sensitization was normalized against the effects of the coadministered agent by culturing control cells (not exposed to prednisolone) in the presence of these agents at similar concentrations. The Src kinase inhibitors used include: Quantification of ANXA2 mRNA expression levels using quantitative real-time PCR Total RNA was extracted from a minimum of 5 Â 10 6 leukemic cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and quantified on a spectrophotometer. Next, RNA was reverse transcribed and the obtained cDNA was used to quantify ANXA2 mRNA expression relative to the housekeeping gene B2M using quantitative real-time PCR analysis. For this, PCR products were amplified using the DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, Finland) according to the manufacturer's recommendations, using SYBR Green as a fluorophore to detect transcripts on an ABI Prism 7900 sequence detection system (Applied Biosystems, Life Technologies Europe BV, Bleiswijk, The Netherlands). Oligonucleotide primers used for PCR amplification were designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, CO, USA) and purchased from Eurogentec (Seraing, Belgium). Primer sequences for ANXA2 were as follows: forward primer 5 0 -GTGGGCATCATGTTGAC-3 0 and reverse primer 5 0 -TGCACCATCAGTGTTGATA-3 0 . B2M primer sequences were: forward primer 5 0 -GGAGCAATCAGACTTGTCTT-3 0 and reverse primer 5 0 -ATGCGGCATCTTCAAA-3 0 . For each sample, assessment of the ANXA2 mRNA expression levels was carried out in duplicate.
Assessment of protein expression by immunoblot analysis
Annexin A2, FYN, LCK and p11 (S100A10) protein expression were determined by western blot analysis, essentially as described before. 20 Briefly, total cellular protein lysates were resolved on 10% SDSpolyacrylamide gels and transferred to nitrocellulose membranes (Schleichler and Schuell, Dassel, Germany). Membranes were probed with rabbit polyclonal antiannexin A2 (Abcam, Cambridge, UK), mouse monoclonal antiphosphoannexin A2 (Santa Cruz Biotechnology, Santa ANXA2 confers GC resistance in MLL-rearranged infant ALL JAP Spijkers-Hagelstein et al
Cruz, CA, USA), mouse monoclonal anti-FYN (Epitomics Inc., Burlingame, CA, USA), goat polyclonal antiphospho-FYN (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-LCK (Cell Signaling, Danvers, MA, USA), rabbit polyclonal antiphospho-LCK (Abnova, Taipei city, Taiwan) or mouse monoclonal anti-S100A10 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies. Next, membranes were counterstained with IRDye 680/800-labeled secondary antibodies, and the target proteins were visualized using the Odyssey imaging system (LICOR biotechnology, Lincoln, NE, USA). All membranes were reprobed with mouse monoclonal antiactin antibodies (Sigma-Aldrich, St Louis, MO, USA) to assure equal protein loading between lanes.
shRNA-mediated RNA interference
In order to knockdown ANXA2, FYN, LCK or S100A10 expression by means of RNA interference, SEM cells were virally infected by shRNA-expressing pLKO.1 vectors obtained from Sigma (St. Louis, MO, USA). shRNA target sequences were 5 0 -CGG GAT GCT TTG AAC ATT GAA-3 0 for ANXA2, 5 0 -CTT ACC GAT CTG TCT GTC AAA-3 0 for FYN, 5 0 -GCA CAC ATC AGG AGT TCA ATA-3 0 for LCK, and 5 0 -CCA TGA TGT TTA CAT TTC ACA-3 0 for S100A10. A similar vector expressing a non-human targeting shRNA was used as a nonesilencing control. Virus particles were produced by transient transfection of 293 T cells with a mixture of psPAX-2, pMD2G-VSVG and pLKO.1 (3:1:4). Medium was refreshed after 24 h, and virus-containing medium was harvested at 48 h following transfection. Upon filtration through 0.45 mm cellulose acetate filters, the obtained virus stock was used to infect SEM cells. To produce pure populations of shRNA-expressing SEM cells, infected cells were selected with puromycin (1 mg/ml), which is lethal to uninfected cells. Next, annexin A2, FYN, LCK and p11 (S100A10) protein expression was evaluated by immunoblotting to confirm successful knockdown. In addition, the in vitro prednisolone sensitivity in these cells was determined by 4-day MTT assays performed in triplicate as described above.
BrdU cell proliferation assay and cell viability
Cell proliferation was measured using the FITC BrdU Flow Kit (BD Biosciences, San Diego, CA, USA) following the manufacturer's instruction manual. For this, a total of 1 Â 10 6 SEM cells were incubated with 10 mM BrdU for 45 min. Next, the cells were fixated and treated with DNase to expose BrdU epitopes, and subsequently incubated with FITC-conjugated anti-BrdU antibodies. In parallel, total DNA was stained with 7-AAD. This staining combination permits flow cytometric evaluation of actively synthesizing DNA (BrdU incorporation) in terms of cell cycle phases (G0/ 1, S, or G2/M) defined by 7-AAD intensities. These analyses were performed using a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). In addition, trypan blue exclusion was used to microscopically monitor cell expansion of viable cells. For this, the percentage of viable cells at a given time point was derived from the number of viable cells per ml divided by the total amount of cells per ml present in the samples.
Free-cytosolic Ca 2 þ measurement Free-cytosolic Ca 2 þ was stained using Calcium Orange-1 (Invitrogen, Life Technologies, Breda, The Netherlands) and quantified on a flow cytometer (Facs Calibur, Becton Dickinson). For this, leukemic cells were washed twice in phosphate-buffered saline and incubated with 2 mM of Calcium Orange-1 for 1 h at room temperature in the dark. Prior to detection by flow cytometry, the incubated cells were washed twice in phosphate-buffered saline to exclude aspecific binding Calcium Orange-1.
Statistical analysis
Statistical significance in differential ANXA2 expression was determined using the Mann-Whitney U-test. The Kruskall-Wallis test was performed to evaluate differences in in vitro prednisolone response between samples expressing high and low levels of either ANXA2 or S100A10. Spearman's r test was used to assess the correlation between ANXA2 and S100A10 expression. Student's t-test was used to analyze differences in mean cytotoxicity responses. All analyses were two-tailed, and differences were considered statistically significant at P-values o0.05. Event-free survival curves were generated using the Kaplan-Meier method and analyzed by Log-rank (Mantel-Cox) tests. Multivariate analysis was performed using a Cox regression model based on the event-free survival, and the Wald backward test was used for the joint analysis of the in vitro prednisolone response, ANXA2 and S100A10 expression.
RESULTS
Establishing a prednisolone-resistance expression signature for MLL-rearranged infant ALL We here generated a gene-expression signature associated with in vitro prednisolone resistance, by comparing gene-expression profiles (Affymetrix HU133plus2.0 GeneChips) obtained from prednisolone-resistant patients (LC 50 -values 4150 mg/ml; n ¼ 24) with profiles from prednisolone-sensitive patients (LC 50 -values o0.1 mg/ml; n ¼ 19). Linear models for microarray data) analyses revealed differential expression (false-discovery rate o0.05) of 74 probe sets, corresponding to 66 genes (Figure 1a) . The level of separation between resistant and sensitive patients was explored using principal component analysis. This approach revealed a separation, but the presented gene signature was not able to completely isolate both patient groups: some degree of overlap remained present (Figure 1b) . In order to evaluate the relevance of this in vitro prednisolone response signature in relation to in vivo prednisone responses, prednisolone LC 50 values obtained in vitro were compared with in vivo responses established after 7 days of prednisone monotherapy. As shown in Figure 1c , prednisone poor responders are significantly more resistant to prednisolone in vitro compared with prednisone good responders in vivo (Mann-Whitney U-test P ¼ 0.005).
Relation between annexin A2 expression, phosphorylation, and resistance to prednisolone in MLL-rearranged infant ALL One of the genes highly expressed in our MLL-rearranged infant ALL prednisolone-resistance signature represented by three different probe sets (that is, 213503_x_at, 210427_x_at, and 201590_x_at) is ANXA2, encoding human annexin A2 (Figure 1a) . For all probe sets, significantly higher expression was found in prednisolone-resistant MLL-rearranged infant ALL patient samples (Po0.001; Supplementary Figure 1A) . Moreover, ANXA2 expression also appeared significantly higher in MLL-rearranged infant ALL samples when compared with infant ALL patients without MLL translocations or non-infant pediatric (41 year of age) ALL cases (Po0.05; Supplementary Figure 1B) . Moreover, among non-infant pediatric BCP-ALL or T-ALL patients, no differences in ANXA2 expression was observed between prednisolone sensitive and resistant cases (Supplementary Figures 1C and D) .
Using quantitative real-time PCR analysis, we validated highlevel ANXA2 mRNA expression in prednisolone-sensitive (RS4;11 and BEL-1) and prednisolone-resistant (SEM and KOPN8) MLL-rearranged ALL cells lines. The prednisolone response curves for these cell lines are presented in Figure 2a . As shown in Figure 2b , prednisolone-resistant cell lines significantly expressed higher levels of ANXA2 mRNA as compared with the prednisolonesensitive cell lines (Po0.05). Next, we analyzed whether high-level expression of ANXA2 mRNA also translates into increased levels of annexin A2 protein expression and elevated annexin A2 phosphorylation (activation). As depicted in Figure 2c , prednisolone-resistant MLL-rearranged ALL cell lines clearly showed increased annexin A2 protein expression, as well as marked annexin A2 phosphorylation (especially in SEM cells). Annexin A2 phosphorylation was largely absent in the prednisolone-sensitive MLL-rearranged ALL cell lines (Figure 2c ). Similar results were obtained for primary MLL-rearranged infant ALL patient samples. Prednisolone-resistant patient samples (n ¼ 5) showed significantly higher levels of ANXA2 mRNA compared with prednisolonesensitive samples (n ¼ 5) (Po0.01; Figure 2d ). Annexin A2 protein levels only appeared marginally higher in prednisolone-resistant samples, yet these samples evidently displayed increased levels of annexin A2 phosphorylation (Figure 2e ).
shRNA-mediated annexin A2 knockdown blocks proliferation and induces prednisolone sensitivity To further investigate the relation of high-level ANXA2 expression, annexin A2 phosphorylation and prednisolone resistance, we performed ANXA2 knockdown experiments in a MLL-rearranged ALL cell line model. For this, prednisolone-resistant SEM cells were transduced with lentiviral constructs stably expressing shRNAs against human ANXA2 mRNA, or with vectors expressing nontargeting shRNAs as a non-silencing control. Western blot analysis confirmed successful knockdown of the target protein (Figure 3a) . Compared with the non-silencing control, SEM cells challenged with anti-ANXA2 shRNAs appeared to have almost complete loss of both total and phosphorylated annexin A2 expression ( Figure 3a) . As anticipated, downregulation of annexin A2 sensitized resistant SEM cells B20-fold to prednisolone (Figure 3b) . Intriguingly, loss of annexin A2 expression strongly inhibited leukemic cell proliferation (Figure 3c) . A BrdU-based proliferation assay showed a near 30% S-phase reduction in SEM cells in which annexin A2 was suppressed (Figure 3d ). The notion that annexin A2 downregulation leads to impaired proliferation is completely in line with earlier observations. 8, 9, 11 Recently, we demonstrated that high-level expression of the calcium-binding protein complex S100A8/A9 blocks glucocorticoid-induced Ca 2 þ release from the endoplasmic reticulum into the cytosol, and with that inhibits prednisolone-induced apoptosis. 17 To determine whether the calcium-binding protein annexin A2 maintains prednisolone resistance via a similar mechanism, we challenged shANXA2-transduced SEM cells, as well as non-silencing control-transduced cells, to prednisolone (50 mg/ml) and determined the levels of free-cytosolic Ca 2 þ . Interestingly, knockdown of annexin A2 did not lead to increased levels of free-cytosolic Ca 2 þ upon exposure to prednisolone (Supplementary Figure 2) . Thus, in contrast to high-level S100A8/ A9, phosphorylated annexin A2 mediates resistance to prednisolone independent of prednisolone-induced free-cytosolic Ca 2 þ .
Src kinase inhibition blocks annexin A2 phosphorylation and induces prednisolone sensitivity Although high-level ANXA2 expression is associated with prednisolone resistance in MLL-rearranged ALL, the actual factor conferring resistance may in fact be the presence of phosphorylated annexin A2. Phosphorylation of annexin A2 is mediated by Src kinases, a process that requires the inducible adapter protein p11 (encoded by the S100A10 gene). [12] [13] [14] Thus theoretically, Src kinase inhibition should block annexin A2 phosphorylation and by that induce prednisolone sensitivity. As the Src kinase family comprises multiple members (including SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK) with varying substrate specificities, we tested the effects of a broad spectrum of known Src kinase inhibitors on the in vitro prednisolone response in resistant SEM cells. The used inhibitors included PP1, PP2, AZD0530, dasatinib, imatinib, herbamycin A, lavendustin A, piceatannol, SU-6656 and SKI-606, exerting varying specificity towards different members of the Src kinase family. [21] [22] [23] [24] [25] As shown in Figure 4a and Supplementary Figure 3 , only a few of the inhibitors, that is PP1, PP2, imatinib and AZD0530 significantly sensitized SEM cells to prednisolone, whereas the other agents had little or no effect. As expected, PP3, which is structurally comparable to PP2 but represents an inactive agent (commonly used as a negative control for PP2), did not induce prednisolone sensitivity in contrast to PP2 (Figure 4a RUNX2  RUNX2  SUPT3H  SUPT3H  ATP2A3  GOLGA2L1  PHLDB2  OR2A20P  SERPINE1  PAN3  ERGIC1  SENP7  ZNF43  CD59  CACNA2D4  FKSG32  PARVB  NSUN2  D123  FJH1  GSPT1  BICD2  LACTB  UBP1  B4GALT5  GBP2  MKL1  ALAS1  SAMSN1  PSTPIP2  TLR2  COTL1  CEBPD ANXA2 confers GC resistance in MLL-rearranged infant ALL JAP Spijkers-Hagelstein et al kinase inhibitors on the in vitro prednisolone response in resistant SEM cells is presented in Supplementary Figure 3 . Interestingly, like we observed in our annexin A2 knockdown experiments, all Src kinase inhibitors that were able to induce prednisolone sensitivity also inhibited cell proliferation (Figure 4b ). Although we recently reported that the Src kinase inhibitor PP2 induces prednisolone sensitization by inhibition of S100A8 and S100A9, 17 we here also investigated whether PP2 influences annexin A2 expression. To test this, we incubated SEM cells with PP2 for indicated time points and determined total and phosphorylated annexin A2 protein expression. Interestingly, in addition to inhibiting S100A8/S100A9, 17 PP2 clearly inhibited annexin A2 phosphorylation (Figure 4c) . Apart from the fact that these results demonstrate that several Src kinase inhibitors are indeed capable of inducing prednisolone sensitivity in MLLrearranged ALL, these data may also point out which of the Src kinases have prominent roles in annexin A2 phosphorylation. As the prednisolone-sensitizing Src inhibitors PP1 and PP2 effectively inhibit both FYN and LCK, 21, 22 these may well represent the key kinases that phosphorylate annexin A2. To further investigate whether these Src kinases are indeed important in prednisolone resistance in MLL-rearranged ALL, we separately knocked down FYN and LCK expression using shRNA-mediated RNA interference in prednisolone-resistant SEM cells. Western blot analyses showed that compared to the non-silencing control, anti-FYN and anti-LCK shRNAs markedly down-regulated FYN and LCK protein expression respectively, and inhibited annexin A2 phosphorylation ( Figure 4d) . As a result of FYN and LCK suppression, total annexin A2 expression appeared largely unaffected, whereas phosphorylated annexin A2 was almost completely down-regulated (Figure 4d ). Subsequently, we asked whether FYN and LCK down-regulation would also sensitize MLL-rearranged ALL cells to prednisolone. Unfortunately, no reliable assay results could be obtained for shLCK, as leukemic cell survival in shLCK-transduced SEM cells was poor, and too few cells survived four days of culturing required to determine the in vitro prednisolone response. However, knock-down of FYN clearly led to prednisolone sensitization (Figure 4e) . Again, knock-down of FYN and LCK was accompanied by impaired leukemic cell proliferation (Figure 4f) , supposedly due to the loss of phosphorylated annexin A2.
Relevance of p11 (S100A10) in Src kinase-induced annexin A2 phosphorylation and prednisolone resistance in MLL-rearranged infant ALL As mentioned above, Src kinase-induced phosphorylation of annexin A2 requires the presence of the adapter protein p11 (encoded by S100A10). 13 At the same time, p11 requires partnering with annexin A2 to become stable and protected from proteosome-dependent degradation. 13 Interestingly, in our recently published MLL-rearranged infant ALL gene-expression profiling study, we found S100A10 to be highly expressed in all patients. 26 In fact, S100A10 expression appeared among the top 50 of most significant genes discriminating between MLL-rearranged infant ALL and pediatric precursor B-ALL. 26 Although these data only reflects mRNA expression, which does not necessarily predict the levels of p11 protein expression, we attempted to verify the importance of S100A10 expression regarding prednisolone resistance. First, we determined the relation between VSNnormalized ANXA2 and S100A10 expression (HU133plus2.0 Affymetrix microarray data), and found a positive correlation (Spearman's r test ¼ 0.682, Po0.0001) (Figure 5a) . Next, to test the importance of S100A10 regarding prednisolone resistance, we divided our MLL-rearranged infant ALL patient samples into four groups based on the levels ANXA2 and S100A10 expression as follows: (I) samples expressing low ANXA2 and low S100A10, (II) samples expressing high ANXA2 but low S100A10, (III) low ANXA2 but high S100A10 expression and (IV) samples highly expressing both ANXA2 and S100A10. In this, 'low' and 'high' expression should be interpreted cautiously, as both ANXA2 and S100A10 are expressed at relatively high levels throughout the patient cohort. Therefore, the median expression values were used as cutoff values to classify patients expressing 'high' (that is very high) or 'low' (moderately high) expression levels. Next, we compared in vitro prednisolone sensitivity among these four groups (Figure 5b ). Interestingly, high-level expression of S100A10 appeared a stronger predictor for prednisolone resistance than high ANXA2 expression (Figure 5b ). MLL-rearranged infant ALL samples over-expressing S100A10 at the mRNA level were significantly (Po0.001) more resistant to prednisolone in vitro, regardless of their ANXA2 expression level. In addition, expression of S100A10 appeared more predictive for clinical outcome than ANXA2 expression. MLL-rearranged infant ALL patient with highlevel expression of S100A10 experienced a worse outcome than patients expressing low levels of S100A10 (log-rank test Po0.005). Similar analysis for ANXA2 expression revealed that the correlation with clinical outcome and the level of ANXA2 expression was far less evident (log-rank test P ¼ 0.1278; Figure 5c ). Moreover, multivariate Cox regression analysis demonstrated that S100A10 ANXA2 expression (%) (Relative to RNASEP) S e n s it iv e R e s is t a n t ANXA2 expression (%) (Relative to RNASEP) S e n s it iv e R e s is t a n t Resistant Sensitive phospho-Annexin A2 : Figure 2 . High-level ANXA2 expression confers resistance to prednisolone in MLL-rearranged infant ALL. (a) In vitro prednisolone response curves for the MLL-rearranged ALL cell line models either sensitive (RS4;11 and BEL-1) or resistant (SEM and KOPN8) to prednisolone as determined by 4-day MTT assays. In these cell lines (b) ANXA2 mRNA levels were determined by quantitative RT-PCR analysis, and (c) total and phosphorylated annexin A2 as well as annexin A2 phosphorylation was determined by western blot analysis. (d) Similarly, ANXA2 mRNA levels were determined in primary MLL-rearranged infant ALL patient samples either sensitive (n ¼ 5) or resistant to prednisolone (n ¼ 5) in vitro. (e) Shows annexin A2 and phosphoannexin A2 protein levels in prednisolone resistant (n ¼ 3) and prednisolone-sensitive (n ¼ 3) MLL-rearranged infant ALL patient samples as determined by western blot analysis. *Indicate significant differences with P-values of o0.05, **indicate significant differences with P-values of o0.01.
ANXA2 confers GC resistance in MLL-rearranged infant ALL JAP Spijkers-Hagelstein et al expression is more important in conferring prednisolone resistance then ANXA2 expression (Wald-test P ¼ 0.038).
Moreover, prednisolone-resistant MLL-rearranged cells also displayed higher p11 protein expression when compared with cells sensitive to prednisolone (Figure 5d ). Thus, although highlevel ANXA2 expression, annexin A2 phosphorylation and the presence of (active) Src kinases (like FYN and LCK) to catalyze tyrosine phosphorylation of annexin A2, are associated with prednisolone resistance in MLL-rearranged ALL, this association is largely dependent on S100A10 expression. Apparently, sufficient amounts of p11 protein are necessary for successful phosphorylation of annexin A2 by FYN and LCK. Thus, in case of insufficient availability of p11 protein, FYN-and LCK-mediated phosphorylation of annexin A2 is hindered and should lead to prednisolone sensitivity. To test this hypothesis, we knocked down S100A10 expression by shRNA-mediated RNA interference in prednisoloneresistant SEM cells. Western blot analyses showed that this led to complete downregulation of p11 protein (Figure 5e ). Moreover, although total annexin A2 expression remained unaltered, annexin A2 phosphorylation was indeed suppressed (Figure 5e ). As expected, this sensitized otherwise resistant SEM cells to prednisolone (Figure 5f ), which again was accompanied by a reduction in leukemic cell proliferation (Figure 5g ). DISCUSSION MLL-rearranged infant leukemia is characterized by poor in vitro and in vivo glucocorticoid responses, which are both of prognostic value. 3, 5, 6 Here we demonstrate that, among other genes, ANXA2 (encoding human annexin A2) is highly expressed in prednisolone-resistant MLL-rearranged infant ALL patient samples. Elevated ANXA2 expression appeared to be specific for in vitro prednisolone resistance in MLL-rearranged infant ALL, as ANXA2 expression could not explain prednisolone resistance in non-infant BCP-ALL nor in T-cell ALL. Whether ANXA2 expression is also associated with prednisolone resistance in older children or adults remains to be tested. Furthermore, we show that suppression of annexin A2 expression indeed sensitizes otherwise resistant MLL-rearranged ALL cells to prednisolone. Additional experiments showed that this phenomenon largely depends on FYN-or LCK-induced tyrosine phosphorylation of annexin A2: knockdown of these Src kinases did not affect total annexin A2 protein levels, but severely inhibited annexin A2 phosphorylation, accompanied by the induction of prednisolone sensitivity in prednisolone-resistant MLL-rearranged ALL cells. Thus not ANXA2 expression per se, but rather the presence of phosphorylated annexin A2 confers prednisolone resistance in MLL-rearranged ALL cells. In line with this, several known Src kinase inhibitors (including PP1, PP2, Imatinib, and AZD0530), with preferred specificity towards FYN and LCK, were also capable of sensitizing MLL-rearranged ALL cells to prednisolone.
Unfortunately, little is known about the effectiveness of the inhibitors PP1 and PP2 in acute leukemias. One study in acute myeloid leukemia carrying internal duplications (ITDs) in FLT3 (FLT3-ITD þ ), demonstrated that PP2 reduced constitutive phosphorylation of both LYN and STAT5. Furthermore, PP2 treatment of mice transplanted with FLT3/ITD þ acute myeloid leukemia cells markedly inhibited disease onset and significantly decreased tumor size. 27 Reports describing the efficacy of AZD0530 (or Saracatinib) in acute leukemias do not exist, but AZD0530 has been widely used in clinical trials focusing on varying types of human cancers, including metastatic breast cancer, adenocarcinoma, head and neck squamous cell carcinoma and pancreatic cancer. All of these studies concluded that AZD0530 has no sufficient single-agent activity. [28] [29] [30] [31] We here showed that AZD0530 might be beneficial when implemented in current combination chemotherapy regimes designed for high-risk MLL-rearranged infant ALL patients being resistant to glucocorticoids.
Although imatinib was originally developed to specifically inhibit BCR-ABL-rearranged ALL and chronic myeloid leukemia, it later became apparent that this agent also exhibited inhibitory activity towards Src kinases. 24, 25 These observations seemed promising as the simultaneous inhibition of Src and ABL kinases was proposed to be beneficial for patients with BCR-ABL þ acute 
leukemia
. 32 Yet, the notion that leukemia patients treated with imatinib may acquire resistance to the inhibitor led to the development of more effective ABL kinase inhibitors. 33 However, before clinical testing of Src kinase inhibitors as prednisolonesensitizing drugs can be considered, solid data will need to be generated proving the concept in in vivo mouse models.
Although, based on our data, implementing an effective Src kinase (or annexin A2) inhibitor to overcome glucocorticoid resistance in MLL-rearranged ALL seems logic, the importance of p11 (encoded by S100A10) should not be underestimated. We showed that the level of S100A10 expression represents a better predictor of in vitro prednisolone resistance than the expression of ANXA2. Yet, S100A10 did not appear in our gene expression signature associated with prednisolone resistance in MLL-rearranged infant ALL. This may be explained by the fact that S100A10 is highly expressed in all MLL-rearranged infant ALL patients: our recent gene-expression profiling study showed that S100A10 expression is highly discriminative between MLL-rearranged infant ALL and pediatric BCP-ALL. 26 Moreover, Krivtsov et al. 34 recently showed that S100A10 expression seems to be activated by the MLL fusion protein itself. Nevertheless, despite high-level mRNA expression of S100A10 in MLL-rearranged ALL cells, the p11 protein, requires partnering with annexin A2 to become stable and protected from proteosome-dependent degradation. 13 Thus, detectable levels of p11 protein may only exist in case sufficient annexin A2 protein is available. When that situation occurs, the presence of Src kinases like FYN and LCK are then required for effective annexin A2 phosphorylation, which, as shown in the present study, confers resistance to prednisolone in MLL-rearranged ALL. Therefore, we postulate that inhibition of p11 may well turn out to be the most effective way to dissociate the connection between Src kinase activity and annexin A2 phosphorylation. Interestingly, a recent publication by Reddy et al. 35 reported on the development of 1-substituted 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one analogs that blocks the interaction between p11 and annexin A2, disrupting the physiological complex of annexin A2 and p11 in breast cancer cells. Thus, these specific inhibitors may be intriguing candidates worth testing for their prednisolone-sensitizing effects in MLL-rearranged ALL cells.
In conclusion, we here present a novel mechanism in which Src kinase-induced phosphorylation of annexin A2 has a central role in maintaining prednisolone-resistance in MLL-rearranged infant ALL. Suppression of annexin A2, FYN, LCK, or the adapter protein p11 all result in the inhibition of annexin A2 phosphorylation, and restores susceptibility to prednisolone-induced leukemic cell death. Given the high-level expression of S100A10 in MLL-rearranged infant ALL, we postulate that p11 protein represents an attractive therapeutic target for increasing glucocorticoid responses and with that improve prognosis for patients diagnosed with this aggressive type of leukemia. . The median expression value in the entire cohort was used as the cut-off value. Differences in outcome were statistically analyzed using the log-rank test. *Indicates differences with P-values of o0.005. (d) Western blot analysis was used to determine p11 (S100A10) expression in in vitro prednisolone-resistant (SEM and KOPN8) and prednisolone-sensitive (RS4;11 and BEL-1) cell lines. (e) Western blot analysis showing p11, total annexin A2, and phosphorylated annexin A2 in SEM cells challenged with shRNA-mediated knockdown of S100A10, or non-silencing control (NSC) shRNAs. (f ) In vitro prednisolone response (as determined by 4-day MTT assays) in SEM cells with and without suppressed p11 (S100A10) expression. (g) Viable cell counts at indicated time points in SEM displaying knocked-down p11 (S100A10), or cells transduced with NSC shRNAs. Experiments were performed in duplicate. *Indicate significant differences with P-values of o0.05.
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This article has supplementary appendices (that is, Supplementary  Figures 1-3 ).
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